专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2014054185A Method of detection of novel braf fusion body 审中-公开
标题翻译：检测新型BRAF融合体的方法
公开(公告)号：JP2014054185A
公开(公告)日：2014-03-27
申请号：JP2011004145
申请日：2011-01-12
申请人： Astellas Pharma Inc , アステラス製薬株式会社
发明人： SUZUKI ATSUSHI , ASAUMI MAKOTO , SHINTO NOBUAKI
IPC分类号： C12N15/09 , C12N15/113 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/156
摘要： PROBLEM TO BE SOLVED: To elucidate polynucleotides which is a novel gene responsible for cancers, thereby providing a method of detection of polynucleotides or polypeptides coded by them, and a kit and a primer set for the method.SOLUTION: In the method of detection, a fusion gene comprising a part of CLN3 gene and a part of BRAF gene, or a fusion protein coded by it is detected. The primer set or detection kit comprises a sense primer designed from a part which codes CLN3 and an antisense primer designed from a part which codes BRAF.
摘要翻译：要解决的问题：阐明作为癌基因的新基因的多核苷酸，从而提供一种检测由其编码的多核苷酸或多肽的方法，以及用于该方法的试剂盒和引物组。方法：在检测方法中，检测包含部分CLN3基因和一部分BRAF基因的融合基因或其编码的融合蛋白。引物组或检测试剂盒包含从编码CLN3的部分和从编码BRAF的部分设计的反义引物设计的有义引物。

2. 发明专利

JP2013226075A Novel aurkc fusion 审中-公开
标题翻译：新款AURKC FUSION
公开(公告)号：JP2013226075A
公开(公告)日：2013-11-07
申请号：JP2012100689
申请日：2012-04-26
申请人： Astellas Pharma Inc , アステラス製薬株式会社
发明人： SUZUKI ATSUSHI , KADOYAMA KAZUHISA , ASAMI MAKOTO , NISHIMURA KOICHI
IPC分类号： C12Q1/68 , C07K19/00 , C12N15/09
摘要： PROBLEM TO BE SOLVED: To provide a method for determining a polynucleotide that is a new cancer causative gene and thereby detecting the polynucleotide or a polypeptide that it encodes, and a kit and a primer set therefor.SOLUTION: A method is provided for determining that a fusion gene between part of ZNF264 gene present in some cancer patients and part of AURKC gene is a cancer causative gene, and detecting a polynucleotide being the gene and a polypeptide encoded by the gene. The detection method includes detecting a fusion gene between part of ZNF264 gene and part of AURKC gene, or a fusion protein that it encodes. A primer set or a detection kit includes a sense primer designed from a portion coding ZNF264 and an antisense primer designed from a portion encoding AURKC.
摘要翻译：要解决的问题：提供一种确定作为新的癌症致病基因的多核苷酸，从而检测其编码的多核苷酸或多肽的方法，以及用于其的试剂盒和引物组。方法：提供一种确定方法存在于一些癌症患者的部分ZNF264基因和部分AURKC基因之间的融合基因是癌症致病基因，并且检测作为该基因的多核苷酸和由该基因编码的多肽。该检测方法包括检测部分ZNF264基因和部分AURKC基因之间的融合基因，或其编码的融合蛋白。引物组或检测试剂盒包括由编码ZNF264的部分设计的有义引物和由编码AURKC的部分设计的反义引物。

3. 发明公开

EP2824181A4 NOVEL FGFR3 FUSION PRODUCT 有权
标题翻译：新型FGFR3融合产品
公开(公告)号：EP2824181A4
公开(公告)日：2015-07-15
申请号：EP13757006
申请日：2013-03-07
申请人： ASTELLAS PHARMA INC
发明人： SUZUKI ATSUSHI , ASAUMI MAKOTO , TSUNOYAMA KAZUHISA , NISHIMURA KOUICHI , MORINAKA AKIFUMI , YAMAUCHI TOMOHIRO , YOSHINO MASAYASU , YOSHIZAKI HIROAKI
IPC分类号： C12N15/09 , A61K45/00 , A61P35/00 , C12Q1/68 , G01N33/53
CPC分类号： A61K31/506 , A61K31/4439 , A61K31/496 , C07K14/47 , C07K14/71 , C07K2319/00 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/57407 , G01N33/57423 , G01N33/74 , G01N2333/50
摘要： [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.

4. 发明公开

EP2821402A4 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND 有权转让
标题翻译：芳香族杂环CONNECTION含氮
公开(公告)号：EP2821402A4
公开(公告)日：2015-08-19
申请号：EP13754501
申请日：2013-02-26
申请人： ASTELLAS PHARMA INC , KOTOBUKI PHARMACEUTICAL CO LTD
发明人： KAMEDA MINORU , KURIWAKI IKUMI , IIKUBO KAZUHIKO , HISAMICHI HIROYUKI , KAWAMOTO YUICHIRO , MORITOMO HIROYUKI , SUZUKI TOMOYUKI , FUTAMI TAKASHI , SUZUKI ATSUSHI , TSUNOYAMA KAZUHISA , ASAUMI MAKOTO , TOMIYAMA HIROSHI , NODA ATSUSHI , IWAI YOSHINORI , TOKUZAKI KAZUO , OKADA HARUKI , MIYASAKA KOZO
IPC分类号： C07D239/42 , A61K31/4545 , A61K31/506 , A61P35/00 , A61P43/00 , C07D239/47 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D471/10 , C07D487/20
CPC分类号： C07D239/47 , C07D239/42 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D451/02 , C07D451/04 , C07D453/02 , C07D471/08 , C07D471/10 , C07D487/10 , C07D491/107
摘要： Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

5. 发明专利

PL2824181T3 NOWA FUZJA FGFR3 未知
公开(公告)号：PL2824181T3
公开(公告)日：2019-02-28
申请号：PL13757006
申请日：2013-03-07
申请人： ASTELLAS PHARMA INC
发明人： SUZUKI ATSUSHI , ASAUMI MAKOTO , TSUNOYAMA KAZUHISA , NISHIMURA KOUICHI , MORINAKA AKIFUMI , YAMAUCHI TOMOHIRO , YOSHINO MASAYASU , YOSHIZAKI HIROAKI
IPC分类号： C12Q1/6886

6. 发明专利

EA029140B1 НОВЫЙ СЛИТЫЙ FGFR3 未知
公开(公告)号：EA029140B1
公开(公告)日：2018-02-28
申请号：EA201491655
申请日：2013-03-07
申请人： ASTELLAS PHARMA INC
发明人： SUZUKI ATSUSHI , ASAUMI MAKOTO , TSUNOYAMA KAZUHISA , NISHIMURA KOUICHI , MORINAKA AKIFUMI , YAMAUCHI TOMOHIRO , YOSHINO MASAYASU , YOSHIZAKI HIROAKI
IPC分类号： C12N15/09 , A61K45/00 , A61P35/00 , C12Q1/68 , G01N33/53
摘要： Настоящееизобретениеимеетцельювыявитьполинуклеотидв качественовогогена, ответственногозарак, иимеетцельюсоответственнопредоставитьспособдетектированияполинуклеотидаи полипептида, кодируемогополинуклеотидом, инабордлядетектирования, наборзондови наборпраймеровдлядетектирования. Цельюнастоящегоизобретениятакжеявляетсяпредоставлениефармацевтическойкомпозициидлялечениярака. Способдетектируетслитыйген, составленныйизчастигена FGFR3 ичастигенаТАСС3, илислитыйбелок, кодируемыйслитымгеном. Наборпраймеров, наборзондовилинабордлядетектированиясодержитсмысловойпраймери наборзондов, спроектированныхпочасти, кодирующей FGFR3, иантисмысловойпраймери наборзондов, спроектированныхпочасти, кодирующейТАСС3. Посколькуингибиторполипептидадемонстрируетпротивоопухолевыйэффект, предоставляетсяфармацевтическаякомпозициядлялечениярака, которыйявляетсяположительнымлибопослитомугену, либопополипептиду.

7. 发明专利

AU2013227139B2 Nitrogen-containing aromatic heterocyclic compound 未知
公开(公告)号：AU2013227139B2
公开(公告)日：2017-02-16
申请号：AU2013227139
申请日：2013-02-26
申请人： ASTELLAS PHARMA INC , KOTOBUKI PHARMACEUTICAL CO LTD
发明人： KAMEDA MINORU , KURIWAKI IKUMI , IIKUBO KAZUHIKO , HISAMICHI HIROYUKI , KAWAMOTO YUICHIRO , MORITOMO HIROYUKI , SUZUKI TOMOYUKI , FUTAMI TAKASHI , SUZUKI ATSUSHI , TSUNOYAMA KAZUHISA , ASAUMI MAKOTO , TOMIYAMA HIROSHI , NODA ATSUSHI , IWAI YOSHINORI , TOKUZAKI KAZUO , OKADA HARUKI , MIYASAKA KOZO
IPC分类号： C07D239/42 , A61K31/4545 , A61K31/506 , A61P35/00 , A61P43/00 , C07D239/47 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D471/10 , C07D487/20
摘要： Provided is a compound that is useful as a prophylactic and/or therapeutic agent for bladder cancer. The inventors studied compounds having FGFR-inhibiting activity and completed the present invention upon confirming that the nitrogen-containing aromatic heterocyclic compound of the present invention has FGFR1-, 2-, and/or 3-inhibiting activity, particularly mutant FGFR3-inhibiting activity. This nitrogen-containing aromatic heterocyclic compound can be used as a therapeutic agent for a variety of cancers in which FGFR1, 2 and/or 3 play a role, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple-negative breast cancer, uterine cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

8. 发明专利

CA2866611C NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND 未知
公开(公告)号：CA2866611C
公开(公告)日：2020-01-07
申请号：CA2866611
申请日：2013-02-26
申请人： ASTELLAS PHARMA INC , KOTOBUKI PHARMACEUTICAL CO LTD
发明人： KAMEDA MINORU , KURIWAKI IKUMI , IIKUBO KAZUHIKO , HISAMICHI HIROYUKI , KAWAMOTO YUICHIRO , MORITOMO HIROYUKI , SUZUKI TOMOYUKI , FUTAMI TAKASHI , SUZUKI ATSUSHI , TSUNOYAMA KAZUHISA , ASAUMI MAKOTO , TOMIYAMA HIROSHI , NODA ATSUSHI , IWAI YOSHINORI , TOKUZAKI KAZUO , OKADA HARUKI , MIYASAKA KOZO
IPC分类号： C07D239/42 , A61K31/4545 , A61K31/506 , A61P35/00 , A61P43/00 , C07D239/47 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D471/10 , C07D487/20
摘要： Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

9. 发明专利

EA026953B1 АЗОТСОДЕРЖАЩЕЕ АРОМАТИЧЕСКОЕ ГЕТЕРОЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ 未知
公开(公告)号：EA026953B1
公开(公告)日：2017-06-30
申请号：EA201491595
申请日：2013-02-26
申请人： ASTELLAS PHARMA INC , KOTOBUKI PHARMACEUTICAL CO LTD
发明人： KAMEDA MINORU , KURIWAKI IKUMI , IIKUBO KAZUHIKO , HISAMICHI HIROYUKI , KAWAMOTO YUICHIRO , MORITOMO HIROYUKI , SUZUKI TOMOYUKI , FUTAMI TAKASHI , SUZUKI ATSUSHI , TSUNOYAMA KAZUHISA , ASAUMI MAKOTO , TOMIYAMA HIROSHI , NODA ATSUSHI , IWAI YOSHINORI , TOKUZAKI KAZUO , OKADA HARUKI , MIYASAKA KOZO
IPC分类号： C07D239/42 , A61K31/4545 , A61K31/506 , A61P35/00 , A61P43/00 , C07D239/47 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D471/10 , C07D487/20
摘要： Заявленосоединение, котороеможетиспользоватьсяв качествепрофилактическогои/илитерапевтическогосредстваприракемочевогопузыря. Врезультатеисследованийсоединений, обладающихингибиторнойактивностьюв отношении FGFR, обнаружили, чтоазотсодержащиеароматическиегетероциклическиесоединенияформулы (I), где R, Q, L, X, Y, Z, W ир такие, какопределенов формулеизобретения, обладаютингибиторнойактивностьюв отношении FGFR1, FGFR2 и/или FGFR3, вчастностив отношениимутантного FGFR3, и, такимобразом, былосозданонастоящееизобретение. Азотсодержащиеароматическиегетероциклическиесоединенияпонастоящемуизобретениюможноиспользоватьв качестветерапевтическогосредстваприразличныхвидахзлокачественныхопухолей, связанныхс FGFR1, FGFR2 и/или FGFR3, такихкакраклегкогои устойчивыйк гормональнойтерапииракмолочнойжелезы, ракжелудка, тройнойнегативныйракмолочнойжелезыи ракэндометрия, ракмочевогопузыряи глиобластома, вчастностив качествепрофилактическогои/илитерапевтическогосредстваприракемочевогопузыря, положительногопомутации FGFR3.

10. 发明专利

MX2014010327A COMPUESTO HETEROCICLICO AROMATICO QUE CONTIENE NITROGENO. 未知
公开(公告)号：MX2014010327A
公开(公告)日：2014-10-13
申请号：MX2014010327
申请日：2013-02-26
申请人： ASTELLAS PHARMA INC
发明人： MORITOMO HIROYUKI , IIKUBO KAZUHIKO , SUZUKI TOMOYUKI , KAMEDA MINORU , KURIWAKI IKUMI , HISAMICHI HIROYUKI , KAWAMOTO YUICHIRO , FUTAMI TAKASHI , SUZUKI ATSUSHI , TSUNOYAMA KAZUHISA , ASAUMI MAKOTO , TOMIYAMA HIROSHI , NODA ATSUSHI , IWAI YOSHINORI , TOKUZAKI KAZUO , OKADA HARUKI , MIYASAKA KOZO
IPC分类号： C07D239/42 , A61K31/4545 , A61K31/506 , A61P35/00 , A61P43/00 , C07D239/47 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/10 , C07D405/12 , C07D405/14 , C07D413/12 , C07D471/10 , C07D487/20
摘要： Se proporciona un compuesto de utilidad como un agente profiláctico y/o terapéutico para el cáncer de vejiga. Como resultado de estudios en compuestos que tienen una acción inhibidora de FGFR, los presentes inventores hallaron que los compuestos heterocíclicos aromáticos que contienen nitrógeno de la presente invención tienen una acción inhibidora sobre FGFR1, FGFR2 y/o FGFR3, en particular, FGFR3 mutante y, así, se llevó a cabo la presente invención. El compuesto heterocíclico aromático que contiene nitrógeno de la presente invención se puede usar en forma de un agente terapéutico para diversos cánceres relacionados con FGFR1, FGFR2 y/o FGFR3, como cáncer de pulmón y cáncer de mama resistente a terapia hormonal, cáncer de estómago, cáncer de mama triple negativo, cáncer de endometrio, cáncer de vejiga y glioblastoma, en particular como un agente preventivo y/o terapéutico para cáncer de vejiga FGFR3-positivo mutante.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式